Type IA isolated growth hormone deficiency (IGHD) consistent with compound heterozygous deletions of 6.7 and 7.6 Kb at the GH1 gene locus 
SUMMARY
Isolated growth hormone deficiency (IGHD) may result from deletions/mutations in either GH1 or GHRHR genes. The objective of this study was to characterize the molecular defect in a girl presenting IGHD. The patient was born at 41 weeks of gestation from non-consanguineous parents. Clinical and biochemical evaluation included anthropometric measurements, evaluation of pituitary function, IGF-I and IGFBP-3 levels. Molecular characterization was performed by PCR amplification of GH1 gene and SmaI digestion of two homologous fragments flanking the gene, using genomic DNA from the patient and her parents as templates. At 1.8 years of age the patient presented severe growth retardation (height 61.2 cm, -7.4 SDS), truncal obesity, frontal bossing, doll face, and acromicria. MRI showed pituitary hypoplasia. Laboratory findings confirmed IGHD. GH1 gene could not be amplified in samples from the patient while her parents yielded one fragment of the expected size. SmaI digestion was consistent with the patient being compound heterozygous for 6.7 and 7.6 Kb deletions, while her parents appear to be heterozygous carriers for either the 6.7 or the 7. (3) . In patients with severe growth retardation (height less than -4.5 SDS) presenting IGHD, the prevalence of GH1 or GHRHR gene defects, either mutations or deletions, could be as high as 20%, depending on the population (4, 5) . More recently, Alatzoglou and cols. have reported an 11.1% prevalence of GH1 or GHRHR molecular defects in IGHD pedigrees, which increased to 38.6% in familial cases (6) . Familial IGHD has been associated with four Mendelian disorders (7, 8) , including two autosomal recessive (Type IA and IB), one autosomal dominant (Type II) and one X-linked (Type III) form. Type IA IGHD was first described by Ruth Illig and cols. (9) in 1970 in three Swiss siblings with severe short stature, early growth retardation, extreme dwarfism in adulthood, and a particular phenotype. These patients developed high titers of anti-GH antibodies, which arrested their growth response to pituitary-extracted GH treatment. Using Southern blot analysis in these patients, Phillips III and cols. (10) later characterized a homozygous 7.5 Kb deletion that included GH1 gene.
The aim of this report was to characterize the molecular defect in a female patient who fulfilled the criteria for severe IGHD.
SUBJECT AND METHODS

Case report
We report a small-for-gestational-age female patient born from non-consanguineous parents by vaginal delivery after 41 weeks of gestation. Birth weight and length were 2,460 g (-2.0 SDS) and 44 cm (-3.7 SDS), respectively. Both parents presented normal height: father 165.5 cm (-1.07 SDS) and mother 154.5 cm (-1.01 SDS). The patient's target height was 153.7 ± 8.5 cm. The first evaluation, at 10 months of age, showed severe growth retardation (height 57 cm, -5.9 SDS) ( Table 1) . Auxological parameters were expressed in cm and SDS according to Argentinean references (11) . Her physical examination showed truncal obesity, frontal bossing, doll face, and acromicria ( Figure 1A ). She had normal psychomotor development. Laboratory findings confirmed severe growth hormone deficiency with no GH response to an arginine test, low IGF-I and IGFBP-3, and normal GHBP serum levels (Table 2 ). Brain MRI showed severe anterior pituitary hypoplasia ( Figure 1B) . She started rhGH replacement therapy (0.33 mg/kg.week) at 2.4 years of age. Although her growth rate improved during the first 6 months of treatment (12.8 cm/year), afterwards she developed anti-GH antibodies, and her growth velocity decreased to 2.8 cm/year ( Figure  1C ). Levels of IGF-I and IGFBP-3 remained very low on rhGH treatment. 
Hormone assays
Serum growth hormone (GH) secretion was evaluated by an arginine provocative test (0.5 g/kg body weight). GH, IGF-I, IGFBP-3, and ACTH serum levels were measured by chemiluminiscent immunometric assays (ICMA, IMMULITE ® 2000 system, Siemens Healthcare Diagnostics Products Ltd, Gwynedd, UK); cortisol, prolactin, TSH, and free T4 (FT4), by electrochemiluminescence assays (ECLIA, Roche Diagnostics GmbH, Mannheim, Germany) using a Cobas e411 analyzer. IGF-I levels were also measured by an in house RIA after serum extraction by the acid-ethanol method followed by cryoprecipitation (12) , and GHBP serum concentration was determined by an in house timeresolved fluorometric immunofunctional assay modified from Fisker and cols. (13, 14) . Anti-GH antibodies were determined by an in house ELISA as follows: A 96-well plate was coated with rhGH and non-specific sites on the coated wells were blocked with phosphate buffer (PBS; pH = 7.4) containing BSA (2 g/L). After removal of the blocking solution, the serum sample (diluted 1/10 in PBS) was added and incubated overnight at 4°C. The plate was washed and incubated for two hours with rabbit polyclonal horseradish peroxidase-labeled total anti-human IgG (DakoCytomation, Glostrup, Denmark). The plate was washed and the substrate (tetramethyl benzidine) was added. After 5 minutes, the reaction was stopped by addition of sulfuric acid, and absorbance was determined at 450 nm. A. GH1 gene amplification (1.5% agarose gel electrophoresis, ethidium bromide staining). GH1 gene PCR amplification yielded no product using the proband's genomic DNA as template (P), while her parents (M, F) showed one band of the expected size (2,700 bp), similar to normal controls (C 1 , C 2 ). Mk: 100 bp DNA ladder. B. Schematic representation of GH1 gene in the cluster context, and genomic organization resulting from 6.7 and 7.6 Kb deletions. 1F, 1R: oligonucleotide primers for GH1 gene PCR amplification. 2F, 2R: oligonucleotide primers for simultaneous PCR amplification of 5' and 3' homologous flanking sequences (white and shaded boxes, respectively) that give rise to the 6.7 Kb deletion. Grey boxes: homologous regions that give rise to 7.6 Kb deletion upon unequal recombination. Dotted arrows indicate SmaI restriction enzyme sites present in 3' homologous flanking region. C. SmaI digestion (5% polyacrylamide gel electrophoresis, ethidium bromide staining). Fragment pattern was consistent with the father (F) being heterozygous carrier for 6.7 Kb deletion, and the patient (P), compound heterozygous for 6.7 and 7.6 Kb deletions. Unfortunately, the band pattern for the mother (M), presumably carrier of a 7.6 Kb deletion, could not be distinguished from a normal control (C1 
Magnetic resonance imaging (MRI):
MRI examination was carried out in sagittal and coronal T1 images of the brain, sellar and suprasellar structures, with and without gadolinium contrast.
Molecular characterization
Genomic DNA was isolated from peripheral venous blood by cetyltrimethylammonium bromide (CTAB) lysis buffer and chloroform-isoamyl alcohol extraction (15) . Written informed consent for molecular studies was obtained from the parents.
PCR amplification of the whole GH1 gene (Gene ID 2688, RefSeqGene: NG_011676.1) was performed using GoTaq ® DNA polymerase (Promega Corporation, Madison, USA) and oligonucleotide primers GH1F (5'-ccagcaatgctcagggaaag-3') and GH1R (5'-tgtcccaccggttgggcatggcaggtagcc-3') (16). PCR mixtures were denatured for 2 min at 94ºC and submitted to 30 cycles at 92ºC for 1 min; 61ºC for 45 sec; and 68ºC for 3 min, followed by final extension at 68ºC for 10 minutes. The resulting PCR product (2700 bp) was visualized by agarose gel electrophoresis and ethidium bromide staining. Characterization of GH1 gene deletion was performed according to the method by Vnencak-Jones and cols. (17) modified by Mone and cols. (18) . Briefly, two homologous sequences flanking GH1 gene, and the fusion fragments resulting from different GH1 gene dele-tions, were simultaneously amplified by PCR with the following primers: 5'-tccagcctcaaagagcttacagtc-3' (GH2F) and 5'-cgttttctctagtctagatcttcccagag-3' (GH2R). PCR mixtures were denatured at 94ºC for 3 min and submitted to 30 cycles at 94ºC for 1 min; 64ºC for 45 sec; and 72ºC for 3 min, followed by a 10-min final extension at 72ºC. The resulting PCR fragments were digested overnight at 37°C with Smal restriction endonuclease (RO141S, New England Biolabs, MA, USA) according to the manufacturer's protocol, and the digested products were visualized by ethidium bromide staining after electrophoresis on a 5% polyacrylamide gel.
RESULTS
Biochemical evaluation: IGHD was confirmed by lack of response of GH to an arginine test, undetectable levels of IGF-I and IGFBP-3, normal thyroid function (normal to slightly elevated TSH with normal FT4 levels), normal ACTH, and elevated cortisol levels. Prolactin levels were slightly above the upper normal range (Table 2) .
PCR amplification of GH1 gene: GH1 gene PCR amplification yielded no product using two different genomic DNA samples of the proband as template, while her parents showed one amplicon of the expected size, similar to DNA from normal controls (Figure 2A ). This result was suggestive of GH1 gene deletion in the patient.
Characterization of GH1 gene deletion: following PCR amplification of two homologous sequences flanking GH1 gene, the Smal restriction enzyme digestion band pattern obtained was consistent with the patient being compound heterozygous for 6.7 and 7.6 Kb deletions, while her father displayed a pattern consistent with a heterozygous carrier of the 6.7 Kb deletion. The pattern obtained in the mother could not be distinguished from that of a normal control, and was compatible with both the mother having two normal alleles or being a heterozygous carrier of the 7.6 Kb deletion ( Figure 2C ). Unfortunately, only those heterozygous carriers for the 6.7 Kb deletion can be unambiguously detected by this assay, which does not enable the differentiation between normal homozygous individuals and 7.6 Kb deletion heterozygous carriers (19, 20) . As a consequence, we were not able to confirm whether the proband inherited the 7.6 Kb deletion from her mother, or if this deletion arose as a de novo event.
DISCUSSION
The characteristic phenotype of severe GH deficiency or resistance includes craniofacial disproportion, frontal bossing, truncal obesity, doll face, and acromicria. The absence of basal or stimulated GH together with normal secretion of other pituitary hormones, support the diagnosis of IGHD, suggesting a molecular defect in the GH1 gene. This gene is located in the long arm of chromosome 17 (17q24.2) as part of a cluster of 5 homologous genes, arranged from 5' to 3' as follows: GH1, CSHL1 (chorionic somatommamotropin pseudogene), CSH1 (chorionic somatommamotropin gene 1, or placental lactogen), GH2 and CSH2. The cluster genes share a high degree of identity not only in coding, but also in intervening and flanking sequences. The three pairs of homologous sequences present upstream and downstream of GH1 gene provide a basis for the high susceptibility of this gene to suffer unequal recombination events due to misalignment that give rise to the most common gene deletions (20, 21) .
To date, several different length deletions within the GH-gene cluster (6.7, 7.0, 7.6, 45, double deletions) have been characterized as molecular defects in IGHD (20) (21) (22) (23) (24) , with the 6.7 Kb deletion as the most frequent one (80%). These patients show severe growth retardation early in infancy (first 6 months of age), undetectable GH levels and, in most of the cases, they develop anti-GH antibodies that impair growth response to exogenous GH treatment. However, in spite of having the same genetic defect and developing similar anti-GH antibodies titers, growth response to GH treatment may be quite heterogeneous depending on the neutrali zing effects of these antibodies (25, 26) . In our patient, an initial 6-month good response to rhGH therapy slowed down when high titers of anti-GH antibodies developed. Therefore, it appears that rhIGF-I remains as the only alternative therapeutic approach.
Most of the cases reported to date arose in consanguineous families. However, the occurrence of compound heterozygous cases with one deleted and one mutated allele (20, 27, 28) , or different GH1 gene deletions (29) , as the present case, suggests that this diagnosis should be considered in patients with severe growth retardation, particularly in early infancy, even in non-consanguineous families. Since most type-IA IGHD patients develop anti-GH antibodies after rhGH treatment, molecular diagnosis has clinical implications for the management of patients with this condition.
